Affimed N.V. (AFMD)
NASDAQ: AFMD
· Real-Time Price · USD
0.69
-0.01 (-1.43%)
At close: May 09, 2025, 3:59 PM
0.70
1.72%
After-hours: May 09, 2025, 04:05 PM EDT
-1.43% (1D)
| Bid | 0.68 |
| Market Cap | 10.43M |
| Revenue (ttm) | 877K |
| Net Income (ttm) | -69.97M |
| EPS (ttm) | -5.15 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -0.29 |
| Analyst | Buy |
| Ask | 0.83 |
| Volume | 92,831 |
| Avg. Volume (20D) | 104,678 |
| Open | 0.70 |
| Previous Close | 0.70 |
| Day's Range | 0.68 - 0.72 |
| 52-Week Range | 0.52 - 8.95 |
| Beta | 2.07 |
About AFMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AFMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AFMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Affimed N.V. is scheduled to release its earnings on May 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-29.11%
Affimed shares are trading lower. The company repo...
Unlock content with
Pro Subscription
11 months ago
+68.51%
Affimed shares are trading higher after the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.
1 week ago · https://www.marketscreener.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingAn exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improv...